Tech Company Financing Transactions
BioLoomics Funding Round
On 9/19/2023, BioLoomics landed $8.7 million in Seed investment from Innovation Endeavors, Boom Capital and BoxOne Ventures.
Transaction Overview
Company Name
Announced On
9/19/2023
Transaction Type
Venture Equity
Amount
$8,700,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its proprietary platform technology and antibody degrader programs and form strategic partnerships with large pharma companies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boulder, CO Undisclosed
USA
Boulder, CO Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
After seven years of DARPA-funded research in the Rapid Threat Assessment (RTA) program at the University of Colorado, Boulder, a eureka moment led to the founding of BioLoomics. Co-founders Jeremy Jacobsen and Dr. Douglas Chapnick realized the remarkable potential of single-cell testing in the directed evolution of antibodies, employing sophisticated imaging and robotic cell picking.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Doug Chapnick
Co-Founder
Jeremy Jacobsen
Co-Founder
Ted Kee
Browse more venture capital transactions:
Prev: 9/19/2023: ANKA venture capital transaction
Next: 9/19/2023: ARX venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs